BR112022012286A2 - Combinações - Google Patents

Combinações

Info

Publication number
BR112022012286A2
BR112022012286A2 BR112022012286A BR112022012286A BR112022012286A2 BR 112022012286 A2 BR112022012286 A2 BR 112022012286A2 BR 112022012286 A BR112022012286 A BR 112022012286A BR 112022012286 A BR112022012286 A BR 112022012286A BR 112022012286 A2 BR112022012286 A2 BR 112022012286A2
Authority
BR
Brazil
Prior art keywords
disease
compounds
condition
inhibitor
combinations
Prior art date
Application number
BR112022012286A
Other languages
English (en)
Portuguese (pt)
Inventor
Abdi Samatar Ahmed
Ma Jianhui
Li Jiali
Qinhua Huang Peter
Gajanan Hegde Sayee
Duane Bunker Kevin
Donate Fernando
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of BR112022012286A2 publication Critical patent/BR112022012286A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
BR112022012286A 2019-12-20 2020-12-16 Combinações BR112022012286A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US202063009754P 2020-04-14 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
BR112022012286A2 true BR112022012286A2 (pt) 2022-08-30

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012286A BR112022012286A2 (pt) 2019-12-20 2020-12-16 Combinações

Country Status (12)

Country Link
US (1) US20230042653A1 (enExample)
EP (1) EP4069224A4 (enExample)
JP (1) JP2023507799A (enExample)
KR (1) KR20220119428A (enExample)
CN (1) CN115103673A (enExample)
AU (1) AU2020408698A1 (enExample)
BR (1) BR112022012286A2 (enExample)
CA (1) CA3165477A1 (enExample)
IL (1) IL294084A (enExample)
MX (1) MX2022007624A (enExample)
TW (1) TW202135810A (enExample)
WO (1) WO2021127046A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CN101970440A (zh) * 2007-11-28 2011-02-09 先灵公司 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
EP2477628B1 (en) * 2009-09-15 2014-08-20 Merck Sharp & Dohme Corp. Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
RS56680B1 (sr) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US11932650B2 (en) * 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
SG11202003974XA (en) * 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
KR20220044528A (ko) * 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제

Also Published As

Publication number Publication date
AU2020408698A1 (en) 2022-07-14
KR20220119428A (ko) 2022-08-29
WO2021127046A1 (en) 2021-06-24
CN115103673A (zh) 2022-09-23
US20230042653A1 (en) 2023-02-09
TW202135810A (zh) 2021-10-01
CA3165477A1 (en) 2021-06-24
MX2022007624A (es) 2022-08-16
IL294084A (en) 2022-08-01
EP4069224A1 (en) 2022-10-12
EP4069224A4 (en) 2023-12-20
JP2023507799A (ja) 2023-02-27

Similar Documents

Publication Publication Date Title
BR112022012280A2 (pt) Combinações
BR112022012281A2 (pt) Combinações
BR112022012283A2 (pt) Combinações
BR112022012278A2 (pt) Combinações
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112022023254A2 (pt) Monoterapias e terapias de combinação
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
MX389450B (es) Compuesto novedoso de pirimidina condensada o sal del mismo.
BR112022012266A2 (pt) Combinações
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112022010082A2 (pt) Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
EA202191519A1 (ru) Модуляторы trex1
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2859 DE 21-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.